NWBT to Initiate Phase III Trial for Prostate Cancer

Northwest Biotherapeutics (NWBT) has received clearance from the FDA to
begin assessment of its cell-based dendritic cell product candidate,
DCVax-Prostate, in a Phase III clinical trial.

This trial is based on promising clinical data from a previously
conducted Phase I/II clinical trial. The double-blinded,
placebo-controlled, Phase III clinical trial is expected to enroll
roughly 600 patients at 30 to 50 sites throughout the U.S.

Northwest Biotherapeutics previously received clearance through the FDA
for a Phase II clinical trial for DCVax-Brain, a promising new treatment
for Glioblastoma Multiforme which is the most common, and lethal form of
brain cancer. The company intends to begin this multisite clinical trial
later this year. In addition, the DCVax platform can be used for
multiple cancer indications, and NWBT has completed preclinical work
targeted for a Phase I clinical trial for non-small cell lung cancer and
head and neck cancer.